Article in Physics in medicine and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors at 3 institutions in 2 countries.
Molly M McCullochDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.ORCID 0000-0002-7531-1263
Guillaume CazoulatDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.ORCID 0000-0003-2042-7602
Alexandra C FordDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.ORCID 0000-0002-2692-7539
Baher ElgohariDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.ORCID 0000-0001-7694-6466
Houda BahigDepartment of Clinical Oncology and Nuclear Medicine, Mansoura University, Mansoura, Dakahlia 35516, Egypt.ORCID 0000-0001-9508-0602
Andrew D KimDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.
Hesham ElhalawaniDepartment of Clinical Oncology and Nuclear Medicine, Mansoura University, Mansoura, Dakahlia 35516, Egypt.ORCID 0000-0001-9848-2623
Renjie HeDepartment of Clinical Oncology and Nuclear Medicine, Mansoura University, Mansoura, Dakahlia 35516, Egypt.ORCID 0000-0001-9166-6286
Jihong WangDepartment of Clinical Oncology and Nuclear Medicine, Mansoura University, Mansoura, Dakahlia 35516, Egypt.ORCID 0000-0003-0073-7443
Yao DingDepartment of Clinical Oncology and Nuclear Medicine, Mansoura University, Mansoura, Dakahlia 35516, Egypt.ORCID 0000-0002-0559-5846
Abdallah Sr MohamedDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.ORCID 0000-0002-4304-7234
Daniel F PolanDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, United States of America.ORCID 0000-0002-8182-8832
Jason B KingDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.ORCID 0000-0002-3866-7420
Christine B PetersonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.ORCID 0000-0003-3316-0468
Andrea N OhrtDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.ORCID 0000-0003-0085-9926
Clifton D FullerDepartment of Radiation Medicine, School of Medicine, Oregon Health and Science University, Portland, OR 97239, United States of America.ORCID 0000-0002-5264-3994
Stephen Y LaiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.ORCID 0000-0001-8301-7286
Kristy K BrockDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America.ORCID 0000-0001-9364-5040
The University of Texas MD Anderson Cancer Center · USMansoura University · EGUniversity of Michigan · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1M
Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac deviceR01DE028290 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHRISTODOULEAS, JOHN PAUL, FULLER, CLIFTON DAVID · 2019 to 2023
$4.3M
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR01DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2016 to 2020
$2.9M
Comprehensive Training Program in Imaging Science and InformaticsT32EB007507 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI MARKEY, MIA K, RYLANDER, HENRY GRADY · 2009 to 2024
$2.7M
SMART-ACT: Spatial Methodologic Approaches for Risk Assessment and Therapeutic Adaptation in Cancer TreatmentR01CA214825 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2017 to 2019
$1.1M
imaging Radiation-Associated Dysphagia (iRAD)R01CA218148 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FULLER, CLIFTON DAVID, HUTCHESON, KATHERINE ARNOLD · 2017 to 2019
$810k
Fellow and Resident Radiation Oncology iNtensive Training in Imaging and Informatics to Empower Research Careers (FRONTI2ER)R25EB025787 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAS, PRAJNAN, FULLER, CLIFTON DAVID · 2018 to 2022
$535k
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR56DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2015 to 2015
purposeEarly animal studies suggest that parotid gland (PG) toxicity prediction could be improved by an accurate estimation of the radiation dose to sub-regions of the PG. Translation to clinical investigation requires voxel-level dose accumulation in this organ that responds volumetrically throughout treatment. To date, deformable image registration (DIR) has been evaluated for the PG using only surface alignment. We sought to develop and evaluate an advanced DIR technique capable of modeling these complex PG volume changes over the course of radiation therapy. MATERIALS AND
methodsPlanning and mid-treatment magnetic resonance images from 19 patients and computed tomography images from nine patients who underwent radiation therapy for head and neck cancer were retrospectively evaluated. A finite element model (FEM)-based DIR algorithm was applied between the corresponding pairs of images, based on boundary conditions on the PG surfaces only (Morfeus-spatial). To investigate an anticipated improvement in accuracy, we added a population model-based thermal expansion coefficient to simulate the dose distribution effect on the volume change inside the glands (Morfeus-spatialDose). The model accuracy was quantified using target registration error for magnetic resonance images, where corresponding anatomical landmarks could be identified. The potential clinical impact was evaluated using differences in mean dose, median dose, D98, and D50 of the PGs.
resultsIn the magnetic resonance images, the mean (±standard deviation) target registration error significantly reduced by 0.25 ± 0.38 mm (p = 0.01) when using Morfeus-spatialDose instead of Morfeus-spatial. In the computed tomography images, differences in the mean dose, median dose, D98, and D50 of the PGs reached 2.9 ± 0.8, 3.8, 4.1, and 3.8 Gy, respectively, between Morfeus-spatial and Morfeus-spatialDose.
conclusionDifferences between Morfeus-spatial and Morfeus-spatialDose may be impactful when considering high-dose gradients of radiation in the PGs. The proposed DIR model can allow more accurate PG alignment than the standard model and improve dose estimation and toxicity prediction modeling.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Biomechanical modeling of radiation dose-induced volumetric changes of the parotid glands for deformable image registration. · full record | OpenQuestion